TAM Receptors Emerge as Promising New Target for Rheumatoid Arthritis Therapies
Table of Contents
A new review published in Cell & Bioscience suggests the TAM receptor family – encompassing Tyro3, Axl, and MerTK – holds significant potential as a novel therapeutic avenue for rheumatoid arthritis (RA). The findings, released on November 19, 2025, highlight the receptors’ crucial role in regulating immune homeostasis and resolving inflammation, offering a fresh perspective on tackling the debilitating autoimmune disease.
The Role of TAM Receptors in Immune Regulation
TAM receptors are widely expressed throughout the body and are understood to be key regulators of the immune system. Researchers have observed that a deficiency in these receptors in animal models leads to spontaneous chronic inflammation and autoimmune responses, mirroring potential precursors to RA. In humans, these receptors appear to function as a critical inhibitory feedback mechanism, preventing the immune system from spiraling out of control.
“Blocking TAM signaling results in severe defects in the clearance of apoptotic cells (ACs), exacerbates systemic inflammation, and induces overactivation of the immune system, thereby contributing to the onset and progression of RA,” one researcher explained. Conversely, activating these receptors aids in restoring tissue integrity by suppressing immune cell activation, enhancing the removal of dead cells, and promoting tissue repair.
A Dichotomy in Receptor Function: Axl/MerTK vs. Tyro3
The research reveals a nuanced picture, demonstrating that the different TAM receptors play distinct roles in the development of RA. Axl and MerTK have been shown to offer protective benefits, while Tyro3 appears to worsen inflammation and joint destruction.
“This functional dichotomy suggests distinct therapeutic strategies: targeted activation of Axl/MerTK pathways may restore immune balance, whereas Tyro3 inhibition could mitigate synovitis and bone erosion,” the review authors wrote. This divergence is driving a surge in research aimed at harnessing the power of TAM receptors for therapeutic intervention.
Soluble TAM Receptors as Potential Biomarkers
Beyond their therapeutic potential, soluble forms of TAM receptors (sTAM) are emerging as promising biomarkers for evaluating RA disease status. These soluble variants, created through a natural process involving metalloproteinase cleavage, are found in elevated levels in the synovial fluid of RA patients. This suggests they could serve as indicators of disease activity, severity, and prognosis.
Studies have already established correlations between specific sTAM levels and clinical characteristics, including a link between serum sTyro3 and systemic inflammation. However, researchers emphasize the need for standardized detection methods for sTAMs, acknowledging that further investigation and validation are crucial.
Current Therapeutic Landscape & Future Directions
A number of TAM-targeted therapies are currently in clinical development, primarily focusing on small molecules designed to inhibit receptor-ligand binding and/or suppress kinase activity. While initial development has largely centered on oncology indications, the underlying mechanisms suggest potential efficacy in autoimmune diseases like RA. Approximately 20 small-molecule TAM inhibitors have entered clinical evaluation, with 15 remaining in active commercial development.
Researchers are also exploring a diverse range of additional small-molecule inhibitors in the preclinical stage, highlighting the growing interest in this therapeutic area. Future development, the authors suggest, should prioritize receptor-specific modulators to overcome structural challenges and explore combination strategies with existing RA treatments.
Ultimately, a deeper understanding of TAM signaling and its correlation with different disease stages will be essential for unlocking the full therapeutic potential of this pathway. .
